At a glance
- Originator Ceridia
- Class Anti-inflammatories; Antihyperlipidaemics; Irritable bowel syndrome therapies; Naphthalenes
- Mechanism of Action HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Hyperlipidaemia
Most Recent Events
- 22 Sep 2023 Discontinued - Preclinical for Hyperlipidaemia in Australia (PO) prior to September 2023
- 28 Sep 2020 No recent reports of development identified for preclinical development in Hyperlipidaemia in Australia (PO)
- 16 Aug 2016 Chemical structure information added